Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAKAB1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	NOV 21	CAS patent coverage to include exemplified prophetic substances identified in English-, French-, German-, and Japanese-language basic patents from 2004-present
NEWS 3	NOV 26	MARPAT enhanced with FSORT command
NEWS 4	NOV 26	CHEMSAFE now available on STN Easy
NEWS 5	NOV 26	Two new SET commands increase convenience of STN searching
NEWS 6	DEC 01	ChemPort single article sales feature unavailable
NEWS 7	DEC 12	GBFULL now offers single source for full-text coverage of complete UK patent families
NEWS 8	DEC 17	Fifty-one pharmaceutical ingredients added to PS
NEWS 9	JAN 06	The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo
NEWS 10	JAN 07	WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data
NEWS 11	FEB 02	Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS 12	FEB 02	GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS 13	FEB 06	Patent sequence location (PSL) data added to USGENE
NEWS 14	FEB 10	COMPENDEX reloaded and enhanced
NEWS 15	FEB 11	WTEXTILES reloaded and enhanced
NEWS 16	FEB 19	New patent-examiner citations in 300,000 CA/CAplus patent records provide insights into related prior art
NEWS 17	FEB 19	Increase the precision of your patent queries -- use terms from the IPC Thesaurus, Version 2009.01
NEWS 18	FEB 23	Several formats for image display and print options discontinued in USPATFULL and USPAT2
NEWS 19	FEB 23	MEDLINE now offers more precise author group fields and 2009 MeSH terms
NEWS 20	FEB 23	TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms
NEWS 21	FEB 23	Three million new patent records blast AEROSPACE into STN patent clusters
NEWS 22	FEB 25	USGENE enhanced with patent family and legal status display data from INPADOCDB
NEWS 23	MAR 06	INPADOCDB and INPAFAMDB enhanced with new display formats
NEWS 24	MAR 11	EPFULL backfile enhanced with additional full-text applications and grants
NEWS 25	MAR 11	ESBIOBASE reloaded and enhanced
NEWS 26	MAR 20	CAS databases on STN enhanced with new super role

```
                  for nanomaterial substances
 NEWS 27  MAR 23  CA/CAplus enhanced with more than 250,000 patent
                  equivalents from China
 NEWS 28  MAR 30  IMSPATENTS reloaded and enhanced
 NEWS 29  APR 03  CAS coverage of exemplified prophetic substances
                  enhanced

 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN customer
  agreement.  This agreement limits use to scientific research.  Use
  for software development or design, implementation of commercial
  gateways, or use of CAS and STN data in the building of commercial
  products is prohibited and may result in loss of user privileges
  and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 08:18:53 ON 06 APR 2009

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.22       0.22

FILE 'REGISTRY' ENTERED AT 08:19:00 ON 06 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    5 APR 2009  HIGHEST RN 1132636-28-2
DICTIONARY FILE UPDATES:   5 APR 2009  HIGHEST RN 1132636-28-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\10551737 R5 heteroaryl R6 and R8 ring.str
```

chain nodes :
7 12 13 14 17 19
ring nodes :
1 2 3 4 5 6 8 10 11 20
chain bonds :
4-17 5-7 7-8 10-11 11-12 12-13 12-14 17-19
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 8-20 10-20
exact/norm bonds :
4-17 5-7 7-8 8-20 10-11 10-20 12-13 12-14 17-19
exact bonds :
11-12
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

G1:C,O,S

G2:O,S

G3:Cb,Cy,Hy

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 10:CLASS 11:CLASS
12:CLASS 13:CLASS 14:CLASS 17:CLASS 19:CLASS 20:CLASS

L1 STRUCTURE UPLOADED

=> d L1
L1 HAS NO ANSWERS
L1 STR



G1 C,O,S
G2 O,S
G3 Cb,Cy,Hy

Structure attributes must be viewed using STN Express query preparation.

=> file caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.48	0.70

FILE 'CAPLUS' ENTERED AT 08:19:39 ON 06 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 6 Apr 2009 VOL 150 ISS 15
FILE LAST UPDATED: 5 Apr 2009 (20090405/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s L1 SSS full
REGISTRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...

Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

FULL SEARCH INITIATED 08:19:42 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 41318 TO ITERATE

100.0% PROCESSED 41318 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L2 0 SEA SSS FUL L1

L3 0 L2

=> file marpat
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 0.50 187.58

FILE 'MARPAT' ENTERED AT 08:19:49 ON 06 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

FILE CONTENT: 1961-PRESENT VOL 150 ISS 13 (20090403/ED)

MARPAT RECORDS ARE DERIVED FROM INPI DATA FOR 1961-1987

MOST RECENT CITATIONS FOR PATENTS FROM MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US 20090048322 19 FEB 2009
DE 102007039155 19 FEB 2009
EP 2022798 11 FEB 2009
JP 2009035500 19 FEB 2009
WO 2009024087 26 FEB 2009
GB 2451715 11 FEB 2009
FR 2920023 20 FEB 2009
RU 2346937 20 FEB 2009
CA 2618420 24 JAN 2009

The new MARPAT User Guide is now available at:
http://www.cas.org/support/stngen/stndoc/marpat.html.

=> s L1 SSS full
FULL SEARCH INITIATED 08:19:52 FILE 'MARPAT'
FULL SCREEN SEARCH COMPLETED - 79340 TO ITERATE

55.8% PROCESSED 44251 ITERATIONS 20 ANSWERS

89.5% PROCESSED 70985 ITERATIONS 42 ANSWERS

97.8% PROCESSED 77609 ITERATIONS 50 ANSWERS

99.2% PROCESSED 78670 ITERATIONS 52 ANSWERS

```
 99.8% PROCESSED    79187 ITERATIONS                          52 ANSWERS

100.0% PROCESSED    79340 ITERATIONS  (     1 INCOMPLETE)     53 ANSWERS
SEARCH TIME: 00.01.35

L4            53 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY     SESSION
FULL ESTIMATED COST                              131.94     319.52

FILE 'CAPLUS' ENTERED AT 08:21:33 ON 06 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 6 Apr 2009  VOL 150 ISS 15
FILE LAST UPDATED: 5 Apr 2009  (20090405/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s L4
L5            53 L4

=> s L4 AND PY<=2003
              53 L4
        24034941 PY<=2003
L6            18 L4 AND PY<=2003

=> d ibib abs hitstr 1-
YOU HAVE REQUESTED DATA FROM 18 ANSWERS - CONTINUE? Y/(N):y

L6   ANSWER 1 OF 18  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:         2003:796371  CAPLUS  Full-text
DOCUMENT NUMBER:          139:307685
TITLE:                    Preparation of sulfonyl aryl or heteroaryl hydroxamic
                          acid compounds as matrix metalloprotease inhibitors
INVENTOR(S):              Bedell, Louis J.; Mcdonald, Joseph J.; Barta, Thomas
                          E.; Becker, Daniel P.; Rao, Shashidhar N.; Freskos,
                          John N.; Mischke, Brent V.; Getman, Daniel P.;
```

Decrescenzo, Gary A.; Villamil, Clara I.
PATENT ASSIGNEE(S): G.D. Searle and Co., USA
SOURCE: U.S. Pat. Appl. Publ., 200 pp., Cont.-in-part of U.S. Ser. No. 230,209.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 11
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20030191317	A1	20031009	US 2000-728408	20001201 <--
US 6794511	B2	20040921		
WO 9838859	A1	19980911	WO 1998-US4300	19980304 <--
W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GH, GW, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 20010020021	A1	20010906	US 1999-230209	19990624 <--
US 6380258	B2	20020430		
US 20030073845	A1	20030417	US 2001-909227	20010719 <--
US 6696449	B2	20040224		
US 20050075374	A1	20050407	US 2004-867391	20040614

PRIORITY APPLN. INFO.:

WO 1998-US4300	A1	19980304
US 1999-310813	B1	19990512
US 1999-230209	A2	19990624
US 1997-35182P	P	19970304
US 2000-569034	A2	20000511
US 2000-728408	A2	20001201

OTHER SOURCE(S): MARPAT 139:307685
GI



I

AB The title compds. [I; m, n = 0 or 1 and the sum of m + n is 0 or 1; the ring structure W is a 5- or 6-membered aromatic or heteroarom. ring; X = CH2 or (un)substituted NH2; R1 = (i) a substituent containing a 5- or 6-membered cyclohydrocarbyl, heterocyclyl, aryl or heteroaryl radical bonded directly to the depicted SO2 group or (ii) (un)substituted; R2, R3 = H, alkyl, alkenyl, alkynyl, hydroxyalkyl, O- or S-(un)substituted hydroxyalkyl or mercaptoalkyl, hydroxy, thiol, haloalkyl, N-(un)substituted amino, aminoalkyl, aminoalkanoylaminoalkyl, aminoalkoxy, or aminoalkoxyalkyl, heterocyclyl, heterocyclylalkyl, heterocyclyloxy, heterocyclylthio, heteroaryl, heteroarylalkyl, heteroaryloxy, heteroarylthio; or CR2R3 together forms an (un)substituted 4- to 8-membered carbocyclic or heterocyclic ring, that is preferably a 5- or 6-membered ring; R5, R6 = H, alkyl, cycloalkyl, acylalkyl, halo, NO2, HO, cyano, alkoxy, haloalkyl, haloalkoxy, hydroxyalkyl, N-

(un)substituted aminoalkyl or aminoalkoxy, thiol, alkylthio, arylthio, cycloalkylthio, cycloalkoxy, alkoxyalkoxy, perfluoroalkyl, haloalkyl, heterocyclyloxy; or R5 and R6 together with the atoms to which they are bonded form a further aliphatic or aromatic carbocyclic or heterocyclic ring having 5- to 7-members; R20 = each (un)substituted OH, NHOH, or NH2] or pharmaceutically acceptable salts thereof are prepared Also disclosed is a treatment process that comprises administering a contemplated sulfonyl aromatic or heteroarom. ring hydroxamic acid compound in a matrix metalloprotease (MMP) enzyme-inhibiting effective amount to a host having a condition associated with pathol. MMP activity. Thus, thioetherification of 4-phenoxybenzenethiol with 2-fluorobenzaldehyde in the presence of K2CO3 in isopropanol under reflux for 20 h gave 2-(4-phenoxyphenylthio)benzaldehyde which was condensed with tetra-Et dimethylaminomethylenediphosphonate in the presence of NaH in THF at room temperature for 4 h gave to 2-[2-(4-phenoxyphenylthio)phenyl]acetic acid (II). II was oxidized by H2O2 in acetic acid to 2-[2-(4-phenoxyphenylsulfonyl)phenyl]acetic acid which was condensed with O-tetrahydropyranylhydroxylamine using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride in MeCN followed by treatment with p-toluenesulfonic acid in methanol at room temperature for 2 h to give N-hydroxy-2-[2-(4- phenoxyphenylsulfonyl)phenyl]acetamide (III). III and N-hydroxy-2,3-dimethoxy-6-[[4-[4-(trifluoromethyl)phenoxy]-1-piperidinyl]sulfonyl]benzamide showed IC50 of >10,000 nM against MMP-1, 0.3 and 2.4 nM, resp., against MMP-2, and 2 and 2.7 nM, resp., against MMP-13.

REFERENCE COUNT: 70 THERE ARE 70 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:591152 CAPLUS Full-text

DOCUMENT NUMBER: 139:149539

TITLE: Preparation of 7-sulfonyl-3-benzazepine derivatives as modulators of the dopamine receptor for use in pharmaceutical compositions for the treatment of central nervous system (CNS) disorders

INVENTOR(S): Ahmed, Mahmood; Bromidge, Steven Mark; Forbes, Ian Thomson; Gribble, Andrew Derrick; Johnson, Christopher Norbert; King, Francis David; Lightfoot, Andrew P.; Macdonald, Gregor James; Moss, Stephen Frederick; Thompson, Mervyn; Witty, David R.

PATENT ASSIGNEE(S): Smithkline Beecham P.L.C., UK

SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003062205	A1	20030731	WO 2002-EP14824	20021220 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1456178	A1	20040915	EP 2002-796752	20021220

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK

JP 2005518414	T	20050623	JP 2003-562087		20021220
US 20050176759	A1	20050811	US 2004-499776		20040621
PRIORITY APPLN. INFO.:			GB 2001-30702	A	20011221
			GB 2002-12398	A	20020529
			WO 2002-EP14824	W	20021220

OTHER SOURCE(S): MARPAT 139:149539

GI



I



II

AB Sulfonylbenzazepines, such as I [R = aryl, biaryl; R1 = H, alkyl; R2 = H, OH, CN, NO2 CF3, OCF3, alkyl, alkyoxy, alkanoyl, cycloalkyl, alkylsulfonyl, alkylthio, carbamoyl, sulfamoyl, etc.], were prepared for therapeutic use modulating dopamine receptors. These benzazepines are useful for the treatment or prophylaxis of CNS or psychotic disorders, such as depression, anxiety, Alzheimer's disease, age related cognitive decline, ADHD, obesity, mild cognitive impairment, schizophrenia, Parkinson's disease, substance abuse, dyskinetic disorders, bipolar disorder, sexual dysfunction, sleep disorders, emesis, movement disorders, obsessive-compulsive disorders, amnesia, aggression, autism, vertigo, dementia and circadian rhythm disorders. Thus benzazepine derivative II was prepared by reaction of 2,3,4,5-tetrahydro-3-(trifluoroacetyl)-1H-3- benzazepine-7-sulfonyl fluoride with 2-methyl-5-bromoaniline using t-BuLi in THF. The prepared benzazepines were tested for receptor binding activity for dopamine D2 and D3, 5-hydroxytryptamine 5-HT6, 5-HT2A, and 5-HT2C cloned human receptors and showed selectivity for the D2/D3 receptors.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:473266 CAPLUS Full-text
DOCUMENT NUMBER: 139:30862
TITLE: Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
INVENTOR(S): Pacifici, Maurizio; Chandraratna, Roshantha A.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 15 pp., Cont.-in-part of U.S. Ser. No. 464,344.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20030114482	A1	20030619	US 2000-552823	20000420 <--
US 6313168	B1	20011106	US 1999-464344	19991215 <--
EP 1645271	A1	20060412	EP 2005-24409	20001213

```
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, FI, CY, TR
    CA 2407021          A1    20011101    CA 2001-2407021        20010419 <--
    WO 2001080894       A2    20011101    WO 2001-US12742        20010419 <--
    WO 2001080894       A3    20020725
        W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
            CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
            HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
            LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
            SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
            ZA, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
            DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
            BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
    EP 1274456          A2    20030115    EP 2001-928654         20010419 <--
    EP 1274456          B1    20041229
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
    JP 2003531180       T     20031021    JP 2001-577990         20010419 <--
    AT 285794           T     20050115    AT 2001-928654         20010419
    AU 2001255488       B2    20060727    AU 2001-255488         20010419
    HK 1053053          A1    20050610    HK 2003-105084         20030714
    AU 2006233216       A1    20061116    AU 2006-233216         20061027
PRIORITY APPLN. INFO.:                      US 1999-464344      A2 19991215
                                            US 2000-552823      A  20000420
                                            EP 2000-986336      A3 20001213
                                            WO 2001-US12742     W  20010419
OTHER SOURCE(S):        MARPAT 139:30862
```

AB The present invention relates to methods for treating cartilage and bone pathologies, including bone growth related diseases such as osteoarthritis or osteoporosis, comprising administering therapeutically effective amts. of retinoid receptor antagonists or retinoid receptor agonists.

```
L6  ANSWER 4 OF 18  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:       2003:129387  CAPLUS  Full-text
DOCUMENT NUMBER:        138:164054
TITLE:                  Methods and compounds for the use of retinoic acid
                        antagonists and inverse agonists as male
                        anti-fertility agents
INVENTOR(S):            Klein, Elliott S.; Yuan, Yang-Dar; Chandraratna,
                        Roshantha A.
PATENT ASSIGNEE(S):     Allergan, Inc., USA
SOURCE:                 U.S., 19 pp., Cont.-in-part of U.S. Ser. No. 405,748,
                        abandoned.
                        CODEN: USXXAM
DOCUMENT TYPE:          Patent
LANGUAGE:               English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     --------------      ----   --------    -------------------    --------
     US 6521641          B1     20030218    US 2000-591253         20000609 <--
     US 20030144256      A1     20030731    US 2002-304665         20021125 <--
     US 20070054882      A1     20070308    US 2006-503635         20060814
PRIORITY APPLN. INFO.:                      US 1998-103507P     P  19981008
                                            US 1999-405748      B2 19990927
                                            US 2000-591253      A1 20000609
                                            US 2002-304665      B1 20021125
```

OTHER SOURCE(S): MARPAT 138:164054
AB This continuation-in-part patent claims methods and compds. for the inhibition or prevention of spermatogenesis in a male mammal. The compds. claimed are antagonists or inverse agonists inhibiting the transcriptional activation of retinoic receptors RARα, RARβ and/or RARγ. Methods for the use of those compds. as anti-fertility agents to reduce or eliminate spermatozoa in the semen of male mammals to prevent conception are claimed.
REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2002:964331 CAPLUS Full-text
DOCUMENT NUMBER: 138:28938
TITLE: Dyeing composition for keratinous fibers comprising a particular dicationic diazo dye
INVENTOR(S): Vidal, Laurent; David, Herve
PATENT ASSIGNEE(S): L'oreal, Fr.
SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002100834	A1	20021219	WO 2002-FR1980	20020610 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
FR 2825703	A1	20021213	FR 2001-7613	20010611 <--
FR 2825703	B1	20080404		
AU 2002319365	A1	20021223	AU 2002-319365	20020610 <--
EP 1399425	A1	20040324	EP 2002-748945	20020610
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2002010995	A	20040608	BR 2002-10995	20020610
CN 1541207	A	20041027	CN 2002-815684	20020610
CN 100429203	C	20081029		
JP 2005501134	T	20050113	JP 2003-503603	20020610
MX 2003011339	A	20040319	MX 2003-11339	20031208
US 20040244123	A1	20041209	US 2004-480202	20040728
US 7001436	B2	20060221		

PRIORITY APPLN. INFO.: FR 2001-7613 A 20010611
WO 2002-FR1980 W 20020610
OTHER SOURCE(S): MARPAT 138:28938
AB The invention concerns a dyeing composition for dyeing keratinous fibers, in particular human keratinous fibers and more particularly hair, comprising a dicationic diazo dye as well as the dyeing method using same. Synthetic preparation of dicationic diazo dyes are described.
REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:868719 CAPLUS Full-text
DOCUMENT NUMBER: 137:346211
TITLE: Methods of treating hyperlipidemia by using retinoids as antagonists or inverse agonist of a retinoid receptor
INVENTOR(S): Yuan, Yang-Dar; Thacher, Scott M.; Klein, Elliot S.; Chandraratna, Roshantha A.
PATENT ASSIGNEE(S): Allergan, Inc., USA
SOURCE: PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002089781	A2	20021114	WO 2002-US13253	20020426 <--
WO 2002089781	A3	20030327		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20020193403	A1	20021219	US 2001-848159	20010503 <--
CA 2445504	A1	20021114	CA 2002-2445504	20020426 <--
AU 2002259030	A1	20021118	AU 2002-259030	20020426 <--
EP 1392284	A2	20040303	EP 2002-729013	20020426
EP 1392284	B1	20080827		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004532239	T	20041021	JP 2002-586918	20020426
EP 1920771	A2	20080514	EP 2007-22682	20020426
EP 1920771	A3	20080723		
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR				
AT 406159	T	20080915	AT 2002-729013	20020426
US 20050171151	A1	20050804	US 2004-16534	20041217
US 20080214652	A1	20080904	US 2008-72629	20080227

PRIORITY APPLN. INFO.:
US 2001-848159 A 20010503
EP 2002-729013 A3 20020426
WO 2002-US13253 W 20020426
US 2004-16534 B1 20041217

OTHER SOURCE(S): MARPAT 137:346211

AB The current invention relates to methods for treating hyperlipidemia in mammals, including humans. More specifically, the current invention relates to the use of retinoid or retinoid derivative that is able to act as an antagonist or inverse agonist of a retinoid receptor to treat hyperlipidemia.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2001:798081 CAPLUS Full-text
DOCUMENT NUMBER: 135:339297
TITLE: Use of retinoid receptor antagonists or agonists in

the treatment of cartilage and bone pathologies
INVENTOR(S): Pacifici, Maurizio; Chandraratna, Roshantha A.
PATENT ASSIGNEE(S): Allergan Sales, Inc., USA
SOURCE: PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001080894	A2	20011101	WO 2001-US12742	20010419 <--
WO 2001080894	A3	20020725		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 20030114482	A1	20030619	US 2000-552823	20000420 <--
CA 2407021	A1	20011101	CA 2001-2407021	20010419 <--
EP 1274456	A2	20030115	EP 2001-928654	20010419 <--
EP 1274456	B1	20041229		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003531180	T	20031021	JP 2001-577990	20010419 <--
AT 285794	T	20050115	AT 2001-928654	20010419
AU 2001255488	B2	20060727	AU 2001-255488	20010419
HK 1053053	A1	20050610	HK 2003-105084	20030714
AU 2006233216	A1	20061116	AU 2006-233216	20061027
PRIORITY APPLN. INFO.:			US 2000-552823 A	20000420
			US 1999-464344 A2	19991215
			WO 2001-US12742 W	20010419

OTHER SOURCE(S): MARPAT 135:339297
AB The present invention relates to methods for treating cartilage and bone pathologies, including bone growth related diseases such as osteoarthritis or osteoporosis, comprising administering therapeutically effective amts. of retinoid receptor antagonists or retinoid receptor agonists.
REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2001:452848 CAPLUS Full-text
DOCUMENT NUMBER: 135:41045
TITLE: Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
INVENTOR(S): Pacifici, Maurizio; Chandraratna, Roshantha A.
PATENT ASSIGNEE(S): Allergan Sales, Inc., USA
SOURCE: PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2001043732	A2	20010621	WO 2000-US33697	20001213 <--
WO 2001043732	A3	20020321		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 6313168	B1	20011106	US 1999-464344	19991215 <--
CA 2394210	A1	20010621	CA 2000-2394210	20001213 <--
EP 1248602	A2	20021016	EP 2000-986336	20001213 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

JP 2003519103	T	20030617	JP 2001-544671	20001213 <--
AU 784189	B2	20060216	AU 2001-22593	20001213
EP 1645271	A1	20060412	EP 2005-24409	20001213

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR

PRIORITY APPLN. INFO.:	US 1999-464344	A	19991215
	EP 2000-986336	A3	20001213
	WO 2000-US33697	W	20001213

OTHER SOURCE(S): MARPAT 135:41045

AB The present invention relates to methods for treating cartilage and bone pathologies, including bone growth related diseases such as osteoarthritis, comprising administering therapeutically effective amts. of retinoid receptor antagonists. AG1-X2 ion exchange beads were soaked for 1 h in a solution of 4-[[5,6-dihydro-5,5-dimethyl-8-(4-methylphenyl)-2- naphthalenyl]ethynyl]-benzoic acid (AGN 109) and implanted in the vicinity of the prospective humeral mesenchymal condensation in stage 21-22 chick embryos and determined whether humerus development had been impaired by day 10 in vivo. AGN 109-containing beads showed striking effects on humerus development.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2001:396864 CAPLUS Full-text

DOCUMENT NUMBER: 135:19632

TITLE: Preparation of pyrazolyl- and pyrrolylalkanoic acid derivatives with hypoglycemic and hypolipidemic activity

INVENTOR(S): Momose, Yu; Maekawa, Tsuyoshi; Odaka, Hiroyuki; Kimura, Hiroyuki

PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan

SOURCE: PCT Int. Appl., 375 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001038325	A1	20010531	WO 2000-JP7877	20001109 <--

W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, RO,

RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2390923	A1	20010531	CA 2000-2390923	20001109	<--
JP 2001226350	A	20010821	JP 2000-347462	20001109	<--
JP 3723071	B2	20051207			
BR 2000015466	A	20020806	BR 2000-15466	20001109	<--
EP 1228067	A1	20020807	EP 2000-974857	20001109	<--
EP 1228067	B1	20040714			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
HU 2002003165	A2	20030128	HU 2002-3165	20001109	<--
HU 2002003165	A3	20040329			
JP 2003137865	A	20030514	JP 2002-315096	20001109	<--
NZ 519238	A	20031128	NZ 2000-519238	20001109	<--
AT 271049	T	20040715	AT 2000-974857	20001109	
EP 1457490	A1	20040915	EP 2004-76508	20001109	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
PT 1228067	T	20041130	PT 2000-974857	20001109	
ES 2225252	T3	20050316	ES 2000-974857	20001109	
AU 780948	B2	20050428	AU 2001-13031	20001109	
RU 2252939	C2	20050527	RU 2002-115263	20001109	
CN 1260227	C	20060621	CN 2000-817467	20001109	
NO 2002002108	A	20020708	NO 2002-2108	20020502	<--
MX 2002004647	A	20021031	MX 2002-4647	20020509	<--
US 7179823	B1	20070220	US 2002-129702	20020509	
IN 2002KN00645	A	20050311	IN 2002-KN645	20020513	
ZA 2002003824	A	20031015	ZA 2002-3824	20020514	<--
HK 1045991	A1	20041210	HK 2002-106297	20020827	

PRIORITY APPLN. INFO.:

JP 1999-320317	A	19991110
JP 1999-352237	A	19991210
JP 1999-352236	A	19991210
EP 2000-974857	A3	20001109
JP 2000-347462	A3	20001109
WO 2000-JP7877	W	20001109

OTHER SOURCE(S): MARPAT 135:19632

GI



I



II

AB Title compds. (I) [wherein R1 = (un)substituted hydrocarbon or heterocycle; X = bond, O, S, CO, CS, CR4(OR5), or NR6; R4 and R6 = independently H or (un)substituted hydrocarbon; R5 = H or hydroxyl protective group; m = 0-3; Y =

O, S, SO, SO2, NR7, CONR7, or NR7CO; R7 = H or (un)substituted hydrocarbon; A = (un)substituted aromatic ring; n = 1-8; B = (un)substituted N-containing 5-membered heterocycle; X1 = bond, O, S, SO, SO2, OSO2, or NR16; R16 = H or (un)substituted hydrocarbon; R2 = H or (un)substituted hydrocarbon or heterocycle; W = bond or hydrocarbon; R3 = OR8 or NR9R10; R8 = H or (un)substituted hydrocarbon; R9 and R10 = independently H or (un)substituted hydrocarbon or heterocycle; or R9 and R10 together with the N to which they are attached may form a ring] were prepared as retinoid-related receptor function regulating agents or insulin resistance improving agents. For example, Et 3-[1-(4-hydroxybenzyl)-4-phenyl-3-pyrrolyl]propionate and 4-chloromethyl-5-methyl-2-(2-thienyl)oxazole were coupled in the presence of K2CO3 in DMF and treated with HCl to give II (77%). At a concentration of 0.001%, II reduced hypoglycemic and hypolipidemic action by 48% and 70%, resp., lowered total cholesterol by 16%, and increased the plasma anti-arteriosclerosis index by 12% compared to non-treatment groups of mice. In addition, II showed potent PPARγ-RXRα heterodimer ligand activity with EC50 of 1.5 nM. I are useful for the prevention or treatment of diabetes mellitus, hyperlipidemia, impaired glucose tolerance, inflammatory diseases, and arteriosclerosis.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 10 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2001:247339 CAPLUS Full-text
DOCUMENT NUMBER: 134:261280
TITLE: Azepinoindolone derivatives as poly(ADP-ribose) polymerase inhibitors
INVENTOR(S): Lubisch, Wilfried; Kock, Michael; Hoeger, Thomas; Grandel, Roland; Mueller, Reinhold; Schult, Sabine
PATENT ASSIGNEE(S): Basf Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001023390	A2	20010405	WO 2000-EP9024	20000915 <--
WO 2001023390	A3	20011227		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 19946289	A1	20010329	DE 1999-19946289	19990928 <--
DE 10039610	A1	20020228	DE 2000-10039610	20000809 <--
CA 2352194	A1	20010405	CA 2000-2352194	20000915 <--
BR 2000007174	A	20010904	BR 2000-7174	20000915 <--
EP 1183259	A2	20020306	EP 2000-974379	20000915 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
HU 2001004917	A2	20020429	HU 2001-4917	20000915 <--
HU 2001004917	A3	20021228		
JP 2003510328	T	20030318	JP 2001-526542	20000915 <--

MX 2001005199	A	20020311	MX 2001-5199		20010524 <--
NO 2001002567	A	20010625	NO 2001-2567		20010525 <--
IN 2001CN00726	A	20050304	IN 2001-CN726		20010525
BG 105650	A	20020228	BG 2001-105650		20010626 <--
PRIORITY APPLN. INFO.:			DE 1999-19946289	A	19990928
			DE 2000-10039610	A	20000809
			WO 2000-EP9024	W	20000915

OTHER SOURCE(S): MARPAT 134:261280

AB Enantiomeric and diastereomeric forms and prodrugs of azepinoindolone derivs. such as 2-(4-(4-n-propylpiperazin-1-yl)phenyl)-1,3,4,5-tetrahydro- 6H-azepino[5,4,3-c,d]indol-6-one are useful as poly(ADP-ribose) polymerase inhibitors. The effectiveness of the title compds. in inhibiting poly(ADP-ribose) polymerase was demonstrated.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2001:78220 CAPLUS Full-text

DOCUMENT NUMBER: 134:125939

TITLE: The use of retinoid receptor antagonists in the treatment of prostate carcinoma

INVENTOR(S): Chandraratna, Roshantha A.; Brown, Geoffrey

PATENT ASSIGNEE(S): Allergan Sales, Inc., USA

SOURCE: PCT Int. Appl., 64 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001007028	A2	20010201	WO 2000-US19849	20000721 <--
WO 2001007028	A3	20010830		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-145287P P 19990723

OTHER SOURCE(S): MARPAT 134:125939

AB Methods for treating prostate cancer comprise administering a therapeutically effective amount of a retinoid receptor antagonist. In addition, the invention provides methods of inhibiting the growth of a prostate carcinoma cell or tumor, the method comprising contacting the cell or tumor with an effective amount of a retinoid receptor antagonist.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2000:240931 CAPLUS Full-text

DOCUMENT NUMBER: 132:274821

TITLE: Male antifertility agents

INVENTOR(S): Klein, Elliott S.; Yuan, Yang-Dar; Chandraratna, Roshantha A.

PATENT ASSIGNEE(S): Allergan Sales, Inc., USA

SOURCE: PCT Int. Appl., 73 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000019990	A2	20000413	WO 1999-US22222	19990924 <--
WO 2000019990	A3	20000720		
W: AU, CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2346687	A1	20000413	CA 1999-2346687	19990924 <--
AU 9961623	A	20000426	AU 1999-61623	19990924 <--
AU 757448	B2	20030220		
EP 1119350	A2	20010801	EP 1999-948451	19990924 <--
EP 1119350	B1	20050223		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002526405	T	20020820	JP 2000-573351	19990924 <--
AT 289507	T	20050315	AT 1999-948451	19990924

PRIORITY APPLN. INFO.: US 1998-103507P P 19981008
WO 1999-US22222 W 19990924

OTHER SOURCE(S): MARPAT 132:274821
GI



I

AB Methods and compns. for inhibiting or preventing spermatogenesis in a male mammal are disclosed. AGN 194310 (I) was prepared and orally administered to rats and was not toxic and expts. showed that daily oral delivery of this RAR antagonist was sufficient to cause spermatogenic arrest.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1999:784149 CAPLUS Full-text
DOCUMENT NUMBER: 132:36180
TITLE: Macromolecular photoinitiators and their applications
INVENTOR(S): Asakura, Toshikage; Ohwa, Masaki; Yamato, Hitoshi; Tatsumi, Asako
PATENT ASSIGNEE(S): Ciba Specialty Chemicals Holding Inc., Switz.

SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9962961	A1	19991209	WO 1999-EP3458	19990520 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9943639	A	19991220	AU 1999-43639	19990520 <--
EP 1086145	A1	20010328	EP 1999-926340	19990520 <--
EP 1086145	B1	20040512		
R: CH, DE, FR, GB, IT, LI				
JP 2002517522	T	20020618	JP 2000-552170	19990520 <--
US 6458864	B1	20021001	US 2000-701457	20001127 <--

PRIORITY APPLN. INFO.: EP 1998-810501 A 19980529
WO 1999-EP3458 W 19990520

OTHER SOURCE(S): MARPAT 132:36180
GI



I

AB The title photoinitiators are prepared by thermal polymerization of a monomer and a photoinitiator containing a chain transfer group. The macrophotoinitiators are polymerized photochem. to give block copolymers. A photoinitiator prepared from I and methacrylic acid was polymerized with styrene using UV irradiation to give a block copolymer.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1998:392757 CAPLUS Full-text
DOCUMENT NUMBER: 129:68148
ORIGINAL REFERENCE NO.: 129:14150h,14151a
TITLE: α-aminoacetophenones as photoinitiators
INVENTOR(S): Ohwa, Masaki; Yamoto, Hitoshi; Birbaum, Jean-Luc; Nakashima, Hiroko; Matsumoto, Akira; Oka, Hidetaka
PATENT ASSIGNEE(S): Ciba Specialty Chemicals Holding Inc., Switz.
SOURCE: Ger. Offen., 46 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent

LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
DE 19753655	A1	19980610	DE 1997-19753655	19971203	<--
DE 19753655	B4	20080515			
IN 1997DE03201	A	20090313	IN 1997-DE3201	19971107	
TW 452575	B	20010901	TW 1997-86116781	19971108	<--
GB 2320027	A	19980610	GB 1997-23965	19971114	<--
GB 2320027	B	20010509			
SG 73482	A1	20000620	SG 1997-4082	19971118	<--
CH 692422	A5	20020614	CH 1997-2735	19971126	<--
BE 1012647	A5	20010206	BE 1997-953	19971127	<--
AU 9746773	A	19980611	AU 1997-46773	19971128	<--
AU 741581	B2	20011206			
US 6022906	A	20000208	US 1997-982147	19971201	<--
CA 2223376	A1	19980606	CA 1997-2223376	19971203	<--
FR 2758139	A1	19980710	FR 1997-15289	19971204	<--
FR 2758139	B1	20010420			
NL 1007707	A1	19980609	NL 1997-1007707	19971205	<--
NL 1007707	C2	19981027			
CN 1184117	A	19980610	CN 1997-125438	19971205	<--
CN 1134456	C	20040114			
ZA 9710956	A	19980615	ZA 1997-10956	19971205	<--
AT 500120	A1	20051015	AT 1997-2069	19971205	
AT 500120	B1	20070315			
JP 10291969	A	19981104	JP 1997-354199	19971208	<--
BR 9706068	A	20000321	BR 1997-6068	19981203	<--
PRIORITY APPLN. INFO.:			EP 1996-810854	A 19961206	
			DE 1997-19753655	T0 19971203	

OTHER SOURCE(S): MARPAT 129:68148

AB The title compds., of specified structure. are prepared for use as initiators of photopolymn. Adding 120 mL PhCl dropwise to 0.41 mol 2-bromo-1-(4-fluorophenyl)2-methyl-1-propanone in 80 mL MeOH containing 0.45 mol NaOMe at 20° gave 90.8 g crude (4-fluorophenyl)-3,3-dimethyl-2-methoxyoxirane which, after vacuum distillation, was refluxed (0.35 mol) with 200 mL morpholine for 26 h to give 88.1 g 1-(4-fluorophenyl)-2-methyl-2-morpholinyl-1-propanone (I). Adding 80 mmol I in AcNMe2 over 14 h to 0.488 mol 1,3-propanedithiol and 22 g K2CO3 in AcNMe2 at 40° and stirring for 5 h gave 1-[4-[(3-mercaptopropyl)thio]phenyl]-2-methyl-2-morpholino-1-propanone. Use of the products in photopolymn. is exemplified.

L6 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1997:361630 CAPLUS Full-text
DOCUMENT NUMBER: 126:330623
ORIGINAL REFERENCE NO.: 126:64259a,64262a
TITLE: Preparation of 4-anilinopyrido[3,4-d]pyrimidines and analogs as protein tyrosine kinase inhibitors
INVENTOR(S): Cockerill, George Stuart; Guntrip, Stephen Barry; Mckeown, Stephen Carl; Page, Martin John; Smith, Kathryn Jane; Vile, Sadie; Hudson, Alan Thomas; Barraclough, Paul; Franzmann, Karl Witold; et al.
PATENT ASSIGNEE(S): Glaxo Group Limited, UK; Cockerill, George Stuart; Guntrip, Stephen Barry; Mckeown, Stephen Carl; Page, Martin John; Smith, Kathryn Jane
SOURCE: PCT Int. Appl., 55 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9713771	A1	19970417	WO 1996-EP4399	19961010 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG				
AU 9672896	A	19970430	AU 1996-72896	19961010 <--
ZA 9608551	A	19970718	ZA 1996-8551	19961010 <--
EP 861253	A1	19980902	EP 1996-934612	19961010 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 11513398	T	19991116	JP 1996-514711	19961010 <--
IN 1996DE02215	A	20050311	IN 1996-DE2215	19961010
US 6169091	B1	20010102	US 1998-51324	19980826 <--

PRIORITY APPLN. INFO.:

GB 1995-20845	A	19951011
GB 1996-14757	A	19960713
WO 1996-EP4399	W	19961010

OTHER SOURCE(S): MARPAT 126:330623
GI



I II

AB Title compds. [I; R = YZ1ZR4; R2 = H, halo, CF3, alkyl, alkoxy; R4 = cycloalkyl, Ph, thienyl, pyridyl, etc.; R6R7 = atoms to complete a (heteroaryl-substituted) heterocyclic ring; X = N or CH; Y = O, OCH2, SO0-2, (alkyl)imino, etc.; Z = O, CH2, NRb, OCH2, etc.; Rb = H or alkyl; NRbR4 = heterocyclyl; Z1 = (un)substituted phenylene] were prepared Thus, 4,6-dichloropyrido[3,4-d]pyrimidine was aminated by 4-(PhCH2O)C6H4NH2 and th product condensed with 5-tributylstannyl-N-methylimidazole to give title compound II. Data for biol. activity of I were given.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1997:205247 CAPLUS Full-text
DOCUMENT NUMBER: 126:205763
ORIGINAL REFERENCE NO.: 126:39656h,39657a,39658a
TITLE: Preparation of organosilicon compounds, and liquid-crystal composition and liquid-crystal display

element
INVENTOR(S): Kondo, Tomoyuki; Matsui, Shuichi; Hachiya, Norihisa; Nakagawa, Etsuo
PATENT ASSIGNEE(S): Chisso Corp., Japan
SOURCE: PCT Int. Appl., 116 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9705144	A1	19970213	WO 1996-JP2103	19960726 <--
W: CN, JP, KR, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CN 1195352	A	19981007	CN 1996-196782	19960726 <--
EP 872484	A1	19981021	EP 1996-925097	19960726 <--
EP 872484	B1	20021002		
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL				
AT 225353	T	20021015	AT 1996-925097	19960726 <--
JP 3751640	B2	20060301	JP 1997-507462	19960726
US 5993690	A	19991130	US 1998-409	19980126 <--

PRIORITY APPLN. INFO.: JP 1995-211211 A 19950727
WO 1996-JP2103 W 19960726

OTHER SOURCE(S): MARPAT 126:205763

AB Organosilicon compds. represented by the general formula Ra-A-(Z1-A1)m-(Z2-A2)n-(Z3-A3)o-Rb [I; at least one of Ra, Rb, Z1, Z2 and Z3 has an SiH2 group; Ra = H or C1-2 alkyl wherein at least one CH2 group may be substituted by SiH2, O, S, CO, CH:CH, C.tplbond.C, or 1,4-cyclobutylene; Rb = a group of any of the Ra groups, halo or cyano; A, A1, A2 and A3 represent each a bivalent ring group; Z1, Z2 and Z3 represent each independently a covalent bond or (CH2)p wherein at least one CH2 group may be substituted by SiH2, O, S, CO, CH:CH or C.tplbond.C; p represents an integer of 1 to 4; m, n and o represent each independently 0 or 1], which are excellent in the compatibility with other liquid-crystal materials, reduced in viscosity, and improved in threshold voltage, are prepared A liquid crystal composition containing at least one silicon compound I and a liquid crystal display device using said liquid crystal composition are claimed. Thus, 10.0 g 4-bromo-4'-butoxybiphenyl was treated dropwise with BuLi in Et2O at -50°, stirred at -50° for 30 min, warmed to room temperature, stirred for 3 h, and resulting reaction mixture was added dropwise to a solution of 11.6 g propyltrichlorosilane in 10 mL THF at -50°, and stirred at -50° for 30 min and at room temperature for 48 h to give 4.6 g 4-propyldichlorosilyl-4'-butoxybiphenyl. The latter compound (3.0 g) was dissolved in Et2O and reduced by LiAlH4 at room temperature for 10 h to give 7.8% 4-propylsilyl-4'-butoxybiphenyl.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1997:134915 CAPLUS Full-text
DOCUMENT NUMBER: 126:144107
ORIGINAL REFERENCE NO.: 126:27853a,27856a
TITLE: Preparation of 5-aminoalkyl-2-(2-alkoxyphenyl)pyrroles having affinity for dopamine D3 receptors and their use in the treatment of psychoses
INVENTOR(S): Watts, Eric Alfred
PATENT ASSIGNEE(S): Smithkline Beecham Plc, UK; Watts, Eric Alfred
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9700243	A1	19970103	WO 1996-EP2498	19960607 <--
W: JP, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 832064	A1	19980401	EP 1996-920811	19960607 <--
R: BE, CH, DE, ES, FR, GB, IT, LI, NL				
JP 11507657	T	19990706	JP 1996-502608	19960607 <--

PRIORITY APPLN. INFO.: GB 1995-12129 A 19950615
WO 1996-EP2498 W 19960607

OTHER SOURCE(S): MARPAT 126:144107
GI



I

AB The title compds. [I; R1 = C1-4 alkyl; R3 = (un)substituted Ph, 5- or 6-membered heterocyclic aromatic group; R2, R4, R5 = H, halo, C1-4 alkyl, etc.; Y = 1-(1-piperidinyl)ethyl, N-substituted 2-pyrrolidinyl, 2-piperidinyl, etc.], dopamine D3 antagonists with potential for the treatment of schizophrenia, were prepared and formulated. Thus, treatment of N-acetylpiperidine with POCl3 followed by addition of 2-[(5-ethylsulfonyl-2-methoxy-4-phenyl)phenyl]-1H-pyrrole in ClCH2CH2Cl, and treatment of the reaction mixture with NaBH4 afforded 38% I [R1 = Me; R2, R5 = H; R3 = Ph; R4 = EtSO2; Y = 1-(1-piperidinyl)ethyl] which showed IC50 of 4 nM at the human D3 receptor.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 18 OF 18 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1996:724140 CAPLUS Full-text
DOCUMENT NUMBER: 125:343103
ORIGINAL REFERENCE NO.: 125:63853a,63856a
TITLE: Optically active liquid crystal compound containing deuterium atoms for display device
INVENTOR(S): Koizumi, Yasuyuki; Demus, Dietrich; Matsui, Shuichi; Miyazawa, Kazutoshi; Sekiguchi, Yasuko; Nakagawa, Etsuo
PATENT ASSIGNEE(S): Chisso Corp., Japan
SOURCE: Eur. Pat. Appl., 88 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 735015	A2	19961002	EP 1996-300655	19960130 <--
EP 735015	A3	19970611		
R: CH, DE, FR, GB, IT, LI				
JP 08325174	A	19961210	JP 1995-347773	19951214 <--
PRIORITY APPLN. INFO.:			JP 1995-100105 A	19950331
OTHER SOURCE(S):	MARPAT 125:343103			

GI



I

AB The title compound is represented by the formula I (R1, R2 = H, cyano, halogen, or alkyl or halogenated alkyl with 1-20 C atoms with the proviso that ≥1 methylene group in the alkyl group may be substituted by O, S, CH=CH, C.tplbond.C, CO, CF=CF, CF2, or a cycloalkane or cycloalkene ring with 3-5 C atoms; Z1-3 = a covalent bond or an alkylene group with 1-4 C atoms with the proviso that ≥1 methylene group in the alkylene group may be substituted by O, S, CH=CH, C.tplbond.C, CO, CF=CF, CF2, or a cycloalkane or cycloalkene ring with 3-5 C atoms; m, n = 0 or 1; rings A, B, C, D = a benzene, bicyclo[1.1.1]pentane, bicyclo[2.1.1]hexane, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, naphthalene, 1,2,3,4-tetrahydronaphthalene, perhydronaphthalene, fluorene, phenanthrene, 9,10-dihydrophenanthrene, indane, indene, cycloalkane, or cycloalkene ring which may be substituted by O, S, or N atoms) with optically active C atoms bonded to D atoms. With the use of the title compound, it is possible to prepare a liquid crystal composition with controlled pitch and spiral direction without the use of a chiral dopant.

=> log off
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
STN INTERNATIONAL LOGOFF AT 08:21:59 ON 06 APR 2009